Dulaglutide Has Higher Adherence and Persistence than Liraglutide and Exenatide QW—One-Year Follow-Up from U.S. Real-World Data

The objective of this retrospective real-world observational study was to compare 1-year adherence and persistence among patients initiating GLP-1 receptor agonists (GLP-1RA), dulaglutide (DULA) vs. liraglutide (LIRA) or DULA vs. exenatide QW (EQW) in the U.S., using claims data between November 2014 and May 2016 (index date=earliest GLP-1RA fill date) from the HealthCore Integrated Research Database (HIRD®). Patients ≥18 years old, with T2DM, no claim for index drug in the 6 months pre-index period, and continuous enrollment 6 months pre- and 1-year post-index were included. DULA users were propensity-matched 1:1 to LIRA (2,427 pairs) or EQW (1,8pairs) users. Matched cohorts were balanced in baseline characteristics and the mean age was 54 years with around 52% males. The key adherence and persistence outcomes are included in the table. At 1-year, DULA users were more likely to be adherent [Proportion of Days Covered (PDC)≥80%] than LIRA (odds ratio [OR]=1.76, 95% CI=[1.56, 1.99]) or EQW users (OR=2.31, 95% CI=[2.00, 2.66]). Cox regression showed that DULA users were less likely to discontinue therapy than LIRA (hazard ratio [HR]=0.75, 95% CI=[0.69, 0.81]) or EQW users (HR=0.58, 95% CI=[0.53, 0.63]). At 1-year follow-up, patients initiating DULA had higher medication adherence, and were more persistent to their treatment compared to patients initiating either LIRA or EQW. Disclosure R. Mody: Employee; Self; Eli Lilly and Company. Q. Huang: Other Relationship; Self; Eli Lilly and Company. M. Yu: Employee; Self; Eli Lilly and Company. R. Zhao: Other Relationship; Self; Eli Lilly and Company. H. Patel: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. M. Grabner: Employee; Self; HealthCore, Inc. L. Fernandez Lando: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company.